| Eric David Reines, MD | |
|
6300 Stevenson Ave, Ste D, Alexandria, VA 22304-3554 | |
| (703) 212-8750 | |
| (703) 212-8752 |
| Full Name | Eric David Reines |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 42 Years |
| Location | 6300 Stevenson Ave, Alexandria, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700889342 | NPI | - | NPPES |
| 503960 | Other | NCPPO | |
| 4091754 | Other | AETNA HEALTHCARE PLANS | |
| 523402A64 | Other | DC | MEDICARE ID |
| 215373 | Other | MDIPA/ALLIANCE PPO PLANS | |
| 6034284 | Medicaid | VA | |
| 097555 | Other | VA | ANTHEM BCBS |
| A582-0001 | Other | BCBS PLANS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 0101042618 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Inova Alexandria Hospital | Alexandria, VA | Hospital |
| Inova Fairfax Hospital | Falls church, VA | Hospital |
| Inova Mount Vernon Hospital | Alexandria, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Infectious Diseases Physicians, Inc. | 9537267513 | 10 |
News Archive
When presented with different terms to describe a clinical trial, parents were far more likely to consent to enroll their child if it was called a "research study" than if it was called a "medical experiment" or a "research project," in large part because they perceived the former as safer, even though that was not necessarily the case, according to a report in IRB: Ethics & Human Research.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).
Therapeutic Hypothermia, a new online open access peer-reviewed journal, will focus on medical treatment which lowers a patient's body temperature to help reduce the risk of ischemic injury to tissues following a period of insufficient blood flow.
We are as old as our arteries, the adage goes, so could reversing the aging of blood vessels hold the key to restoring youthful vitality? The answer appears to be yes, at least in mice, according to a new study led by investigators at Harvard Medical School.
Following a recent investigation, the FDA is considering taking regulatory action to ensure sesame is labeled as an allergen on food packaging.
› Verified 3 days ago
| Entity Name | Infectious Diseases Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326113549 PECOS PAC ID: 9537267513 Enrollment ID: O20070614000677 |
News Archive
When presented with different terms to describe a clinical trial, parents were far more likely to consent to enroll their child if it was called a "research study" than if it was called a "medical experiment" or a "research project," in large part because they perceived the former as safer, even though that was not necessarily the case, according to a report in IRB: Ethics & Human Research.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).
Therapeutic Hypothermia, a new online open access peer-reviewed journal, will focus on medical treatment which lowers a patient's body temperature to help reduce the risk of ischemic injury to tissues following a period of insufficient blood flow.
We are as old as our arteries, the adage goes, so could reversing the aging of blood vessels hold the key to restoring youthful vitality? The answer appears to be yes, at least in mice, according to a new study led by investigators at Harvard Medical School.
Following a recent investigation, the FDA is considering taking regulatory action to ensure sesame is labeled as an allergen on food packaging.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eric David Reines, MD 6300 Stevenson Ave, Ste D, Alexandria, VA 22304-3554 Ph: (703) 212-8750 | Eric David Reines, MD 6300 Stevenson Ave, Ste D, Alexandria, VA 22304-3554 Ph: (703) 212-8750 |
News Archive
When presented with different terms to describe a clinical trial, parents were far more likely to consent to enroll their child if it was called a "research study" than if it was called a "medical experiment" or a "research project," in large part because they perceived the former as safer, even though that was not necessarily the case, according to a report in IRB: Ethics & Human Research.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).
Therapeutic Hypothermia, a new online open access peer-reviewed journal, will focus on medical treatment which lowers a patient's body temperature to help reduce the risk of ischemic injury to tissues following a period of insufficient blood flow.
We are as old as our arteries, the adage goes, so could reversing the aging of blood vessels hold the key to restoring youthful vitality? The answer appears to be yes, at least in mice, according to a new study led by investigators at Harvard Medical School.
Following a recent investigation, the FDA is considering taking regulatory action to ensure sesame is labeled as an allergen on food packaging.
› Verified 3 days ago
George Peter Silis, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 5115 Franconia Road, Sutie G, Alexandria, VA 22310 Phone: 703-922-4222 Fax: 703-922-4253 | |
Dr. Madhusudanan Srambickal Ramaswamy, M.D., M.S. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4320 Seminary Rd, Alexandria, VA 22304 Phone: 703-504-3000 Fax: 571-285-0027 | |
Nabeela Tabassum, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 4810 Beauregard St, Ste 303, Alexandria, VA 22312 Phone: 703-750-0108 Fax: 703-750-0230 | |
Dr. Chinedu Madu, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4825 Mark Center Dr Ste 150, Alexandria, VA 22311 Phone: 703-751-8111 Fax: 703-751-1105 | |
Kim-dung T Nguyen, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 5130 Duke St, 8, Alexandria, VA 22304 Phone: 703-823-2849 Fax: 703-823-2847 | |
Dr. Muhammed F. Khokhar, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4660 Kenmore Ave Ste 810, Alexandria, VA 22304 Phone: 703-823-0333 Fax: 703-823-8611 | |
Tariq Rehman, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4141a Duke St, Alexandria, VA 22304 Phone: 703-461-3556 Fax: 703-461-8075 |